Skip to search formSkip to main contentSkip to account menu

MP Regimen (Mitoxantrone-Prednisone)

Known as: MP Regimen, Mitoxantrone-Prednisone Regimen 
A regimen consisting of mitoxantrone and prednisone used to treat metastatic hormone-refractory prostate cancer.
National Institutes of Health

Related topics

Related topics

3 relations
Metastatic Prostate CarcinomaMitoxantrone HydrochloridePrednisone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
Comparative study or the curative effect of VCR and MP regimen in the initial treatment or multiple myeloma
Objective To compare the therapeutic effect between VAD and MP regimen in initial untreated patients with multiple myeloma(MM… 
1987
1987
[Clinical trial of a combination of human lymphoblastoid interferon (HLBI), melphalan and prednisolone (HLBI-MP) in multiple myeloma].
Six patients with multiple myeloma were treated with HLBI-MP regimen; HLBI 300 X 10(4)U/day daily, Melphalan 4 mg/day p.o. from… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)